Showa Yakuhin Kako Co., Ltd.

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. This follows positive data from the proof-of-concept Phase II stage of the trial and subsequent consultation with the China National Medical Products Administration (“NMPA”). If positive, the data from the trial may be used to support a future New Drug Application (“NDA”) filing. wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options. The first Phase III patient received their initial dose on March 20, 2024. ESLIM-02 is a randomized, double blind, placebo-controlled Phase II/III clinical trial. The objective of the registration stage of the study is to confirm the safety and efficacy of sovleplenib in adult patients with wAIHA. The primary endpoint for the study is the proportion of patients who achieve a durable hemoglobin (Hb) response by Week 24. 21 patients have been enrolled in the study so far and approximately 90 more patients are expected to be enrolled to this registration stage. The lead principal investigators are Dr. Fengkui Zhang of Chinese Academy of Medical Sciences Blood Diseases Hospital, Dr. Bing Han of Chinese Academy of Medical Sciences Peking Union Medical College Hospital and Dr. Liansheng Zhang of Lanzhou University Second Hospital. Additional details may be found at clinicaltrials.gov, using identifier NCT05535933. About Sovleplenib Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide. In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). ESLIM-01 (NCT05029635) is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in patients with primary ITP that met all its endpoints. ITP is an autoimmune disorder that can lead to increased risk of bleeding. The NMPA granted Breakthrough Therapy designation for this indication and accepted the New Drug Application (NDA) for review with Priority Review in January 2024. A dose-finding study in the U.S. is in planning (NCT06291415). About wAIHA and Syk AIHA is an autoimmune disorder characterized by the destruction of red blood cells (“RBCs”) due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8%-11%.1,2 wAIHA is the most common form of the autoimmune hemolytic diseases,3 accounting for about 75-80% of all adult AIHA cases.4 The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc receptor (“FcR”) bearing macrophages is thought to be the pathogenic mechanism in wAIHA.5 Activation of the FcR is associated with a signaling subunit, FcRγ, whose phosphorylation subsequent to receptor binding results in the recruitment and activation of Syk.6 Activated Syk mediates downstream signaling of the activated FcRs in phagocytic cells, resulting in phagocytosis of RBCs.7 In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells.8 Therefore, inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production. About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology medicines now marketed in China, the first of which is also marketed in the U.S. For more information, please visit: or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of sovleplenib for the treatment of patients with wAIHA and the further development of sovleplenib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support an NDA submission of sovleplenib for the treatment of patients with wAIHA or other indications in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the efficacy and safety pro sovleplenib, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for sovleplenib and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com Zhou Yi, Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon +44 (20) 7886 2500 _____________________ REFERENCES 1 Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29 (1):1-9. doi: 10.1016/j.jaut.2007.05.002. 2 Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89 (9):E150-5. doi: 10.1002/ajh.23767. 3 Cotran Ramzi S, Kumar Vinay, Fausto Nelson, Nelso Fausto, Robbins Stanley L, Abbas Abul K. Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders; 2005. p. 637. 4 Gehrs BC, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002; 69:258–271. doi: 10.1002/ajh.10062. 5 Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010; 24(3):195‐210. doi: 10.1016/j.tmrv.2010.03.002. 6 Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex‐mediated inflammation. J Pharmacol Exp Ther. 2006; 319(3):998‐1008. doi: 10.1124/jpet.106.109058. 7 Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018; 14(10):857‐872. doi: 10.1080/1744666x.2018.1521722. 8 Davidzohn N, Biram A, Stoler‐Barak L, Grenov A, Dassa B, Shulman Z. SYK degradation restrains plasma cell formation and promotes zonal transitions in germinal centers. J Exp Med. 2020; 217(3):e20191043. doi: 10.1084/jem.20191043.

超级人源化抗体改造技术：突破传统免疫原性优化的边界 | 晶泰科技·药时代直播间第4期事件：2023年5月30日，摩根士丹利的研报中强调了诺和诺德和礼来开发的减肥神药对医疗技术设备市场的潜在影响。若GLP-1药物的减重效果接近减肥手术，由肥胖疾病主导的医疗技术设备市场格局，将影响数百亿美元的蓝海市场。以往肥胖症治疗药物的疗效微乎其微，以及一系列安全性问题，限制肥胖药物市场的发展。新一代降糖药GLP-1的减肥效果若朝着减肥手术效果般的预期进展，或将得到更广泛的渗透率。摩根士丹利预测，礼来和诺和诺德的GLP-1用于肥胖症的销售额，在2030年将达到250亿美元的市场份额。来源：摩根士丹利若GLP-1药物减肥效果如期，将转化为改善肥胖相关疾病的结果，相应的医疗条件、解决方案都会得到调整。受GLP-1潜在影响风险的领域包括全膝关节置换术(TKA)、被称为CPAP机器的呼吸保健设备、用于白内障手术的人工晶状体(IOL)、用于糖尿病和透析的连续血糖监测(CGM)设备以及心力衰竭设备。这些医疗技术设备市场在2022年的销售额约为300 亿至400亿美元。《JAMA》上的研究表明，已接受减肥手术的骨关节炎OA患者，接受全膝关节置换术(TKA)的患者比例明显减少。GLP-1药物直接导致肥胖患者的体重减少，将间接影响全膝关节置换术(TKA)的需要，全球约有2.4亿人患有症状性骨关节炎OA，约50%接受了全膝关节置换术(TKA)手术。2022年，全球TKA市场规模约占70亿美元，其中主要的竞争者为强生、SNN、SYK、ZBH。摩根士丹利预测GLP-1药物将可能影响TKA超过5亿美元市场。来源：摩根士丹利一份荟萃分析表明，减肥手术还导致其他代谢相关疾病（如阻塞性睡眠呼吸暂停，血脂异常和高血压）的长期缓解率。肥胖是阻塞性睡眠呼吸暂停(CPAP设备主要适应症)的主要原因，瑞思迈(RMD.US)和飞利浦(PHG.US)等阻塞性睡眠呼吸暂停CPAP设备制造商严重受限于GLP-1药物的日益普及。根据2022年的数据，假设药物接受水平最高、对手术的影响最大，摩根士丹利预测GLP-1药物可能会在全球CPAP设备/耗材市场上造成超过20亿美元的损失。来源：摩根士丹利在一项评价减肥手术和白内障疾病关系的队列研究中，60岁以下的年龄组，减肥手术队列的白内障风险降低了29%，减肥能降低白内障的风险。2022年白内障用于人工晶状体(IOL)手术的全球销售额约为40亿美元，总手术约为1500万例，由于市场的主要主体是 60岁以上的人，研究表明在减肥手术的 60岁以上人群中，白内障风险的发展没有任何益处，因此摩根士丹利预测，GLP-1对全球 IOL市场的总体影响小于 1%。来源：摩根士丹利封面图来源：123rf阿尔茨海默病患者家属之后，临床医生们也纷纷分享他们的亲身感受。。。点击阅读原文，与药时代一起快乐学习！

5月30日，摩根士丹利的研报中强调了诺和诺德和礼来开发的减肥神药对医疗技术设备市场的潜在影响。若GLP-1药物的减重效果接近减肥手术，由肥胖疾病主导的医疗技术设备市场格局，将影响数百亿美元的蓝海市场。以往肥胖症治疗药物的疗效微乎其微，以及一系列安全性问题，限制肥胖药物市场的发展。新一代降糖药GLP-1的减肥效果若朝着减肥手术效果般的预期进展，或将得到更广泛的渗透率。摩根士丹利预测，礼来和诺和诺德的GLP-1用于肥胖症的销售额，在2030年将达到250亿美元的市场份额。来源：摩根士丹利若GLP-1药物减肥效果如期，将转化为改善肥胖相关疾病的结果，相应的医疗条件、解决方案都会得到调整。受GLP-1潜在影响风险的领域包括全膝关节置换术(TKA)、被称为CPAP机器的呼吸保健设备、用于白内障手术的人工晶状体(IOL)、用于糖尿病和透析的连续血糖监测(CGM)设备以及心力衰竭设备。这些医疗技术设备市场在2022年的销售额约为300亿至400亿美元。《JAMA》上的研究表明，已接受减肥手术的骨关节炎OA患者，接受全膝关节置换术(TKA)的患者比例明显减少。GLP-1药物直接导致肥胖患者的体重减少，将间接影响全膝关节置换术(TKA)的需要，全球约有2.4亿人患有症状性骨关节炎OA，约50%接受了全膝关节置换术(TKA)手术。2022年，全球TKA市场规模约占70亿美元，其中主要的竞争者为强生、SNN、SYK、ZBH。摩根士丹利预测GLP-1药物将可能影响TKA超过5亿美元市场。来源：摩根士丹利一份荟萃分析表明，减肥手术还导致其他代谢相关疾病（如阻塞性睡眠呼吸暂停，血脂异常和高血压）的长期缓解率。肥胖是阻塞性睡眠呼吸暂停(CPAP设备主要适应症)的主要原因，瑞思迈(RMD.US)和飞利浦(PHG.US)等阻塞性睡眠呼吸暂停CPAP设备制造商严重受限于GLP-1药物的日益普及。根据2022年的数据，假设药物接受水平最高、对手术的影响最大，摩根士丹利预测GLP-1药物可能会在全球CPAP设备/耗材市场上造成超过20亿美元的损失。来源：摩根士丹利在一项评价减肥手术和白内障疾病关系的队列研究中，60岁以下的年龄组，减肥手术队列的白内障风险降低了29%，减肥能降低白内障的风险。2022年白内障用于人工晶状体(IOL)手术的全球销售额约为40亿美元，总手术约为1500万例，由于市场的主要主体是60岁以上的人，研究表明在减肥手术的60岁以上人群中，白内障风险的发展没有任何益处，因此摩根士丹利预测，GLP-1对全球 IOL市场的总体影响小于1%。来源：摩根士丹利END作者 | 牛果来源 | 新康界不想错过赛柏蓝每日资讯，点赞在看⬇️